Dianthus Therapeutics reported third quarter 2026 financial results that exceeded analyst estimates on both the top and bottom lines. The company highlighted significant clinical progress for its lead candidate, claseprubart, including a high response rate in interim CIDP trial data and a confirmed timeline for upcoming MMN results.
Key Highlights
- Positive CIDP Interim Data: An interim responder analysis from the first 40 participants in the Phase 3 CAPTIVATE trial for CIDP showed a 75% response rate, significantly exceeding the company's 50% target.
- MMN Trial on Track: The Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) exceeded its original enrollment target, with top-line results from 46 patients scheduled for December 2026.
- Robust Capital Runway: The company maintained a cash and investment balance of approximately $1.2 billion, which management projects will fund operations into 2030.